Pretransplant Blinatumomab Improves Outcomes in B Cell Acute Lymphoblastic Leukemia Patients Who Undergo Allogeneic Hematopoietic Cell Transplantation

Acute lymphoblastic leukemia (ALL) is the most common cancer in children [1]. It carries an excellent prognosis with 5-year overall survival (OS) rates of up to 90% [2]. Pediatric-inspired intensive regimens are also used to treat adolescents and young adults age 15 to 39 (AYA), with an estimated 3-year OS in this group of 73% [3].

Source: Biology of Blood and Marrow Transplantation - March 8, 2024 Category: Hematology Authors: Ayman Sayyed, Carol Chen, Armin Gerbitz, Dennis Dong Hwan Kim, Rajat Kumar, Wilson Lam, Arjun Datt Law, Jeffrey H. Lipton, Fotios V. Michelis, Igor Novitzky-Basso, Auro Viswabandya, Jonas Mattsson, Ivan Pasic Tags: Full-length article Source Type: research